antitumor activity of the polysaccharide fraction (OPS) obtained by the acid hydrolysis of Klebsiella O3 Lipopolysaccharide (KO3 LPS) isolated from the culture supernatant of the decapsulated mutant strain LEN-1 (03: K1-) against both allogeneic tumor and syngeneic tumor systems in mice was compared with that of KO3 LPS. OPS prolonged the life span of MM2-bearing C3H/He mice by intraperitoneal (i.p.) pre-and post-treatment at the doses of 100 and 1000 mg/kg. However, large amounts of OPS were needed to show the antitumor activity as compared with KO3 LPS. OPS showed no growth inhibitory activity against Meth-A sarcoma in BALB/c mice by i.p., intravenous (i.v.) or intratumoral (i.t.) administration.
Abstract-The
antitumor activity of the polysaccharide fraction (OPS) obtained by the acid hydrolysis of Klebsiella O3 Lipopolysaccharide (KO3 LPS) isolated from the culture supernatant of the decapsulated mutant strain LEN-1 (03: K1-) against both allogeneic tumor and syngeneic tumor systems in mice was compared with that of KO3 LPS. OPS prolonged the life span of MM2-bearing C3H/He mice by intraperitoneal (i.p.) pre-and post-treatment at the doses of 100 and 1000 mg/kg. However, large amounts of OPS were needed to show the antitumor activity as compared with KO3 LPS. OPS showed no growth inhibitory activity against Meth-A sarcoma in BALB/c mice by i.p., intravenous (i.v.) or intratumoral (i.t.) administration.
When 1000 mg/kg of OPS was i.p. administered once a day for 10 days, OPS significantly inhibited the tumor growth of solid type tumor.
On the other hand, KO3 LPS significantly suppressed the growth of Meth A tumor by Lt. administration at the doses of 0.3 and 1.0 mg/kg and showed com plete regression in 8 and 9 out of 10 mice, respectively.
In MM2 tumor, KO3 LPS also showed complete regression in all mice post-treated by i.p. administration at the dose of 1 .0 mg/kg.
These results suggest that OPS has antitumor activity on the tumors used in this study, but the activity was less than that of KO3 LPS. 
Results
Antitumor activities of OPS and K03 LPS against S-180 solid type tumor: Mice were inoculated s.c. with 3x`106 cells on day 0 and were given i.p. or per os (p.o.) graded doses of OPS and K03 LPS once a day for 10 days from day 10 to day 20 after the cell inoculation (Table 1) . When the agents were administered i.p., 1000 mg/kg of OPS and 1 mg/kg of K03 LPS significantly inhibited the tumor growth. Administration by the p.o. route of K03 LPS also showed an inhibitory effect on the tumor growth, but about a thousand-fold dose of this agent by the p.o. route was necessary to obtain an effect similar in degree to that by the i.p. route. OPS did not show any significant effect by the p.o. route.
Antitumor activities of OPS and K03 LPS against Meth-A solid type tumor: Mice were s.c. inoculated with 2 X 105 cells on day 0 and were given graded doses of OPS or K03 LPS once a day according to the indicated schedules and routes (Table 2) . OPS sup pressed the tumor growth by i.v. or intra tumoral (i.t.) administration, but the effect of OPS was weaker than that of K03 LPS. K03 LPS significantly inhibited the tumor growth at doses of 0.1 to 1 .0 mg/kg by i.v. or i.t. administration.
Antitumor activities of OPS and K03 LPS against MM2 ascites type tumor: C3H/He mice were i.p. inoculated with 5 X 105 cells on day 0 and were i.p. given graded doses of OPS or K03 LPS once a day on day -4 as the preadministration or on days +1 to +10 as the postadministration (Table 3) . These agents markedly prolonged the life span of the mice bearing MM2 tumor by both pre and post-administrations.
However, large amounts of OPS were needed to show the antitumor activity compared with that of K03 LPS. 
The lipid A moiety of K03 LPS retains lethal toxicity for mice, whereas OPS is essentially non-toxic (23). Our recent studies have revealed that the polysaccharide moiety plays an important role as well as the lipid A moiety in the extraordinarily strong adjuvant activity of K03 LPS in augmenting antibody responses and delayed-type hypersensitivity to protein antigens in mice (7, 8, 24) . We also found that the adjuvant activity of OPS was weak and about a fifty-fold greater amount of OPS was necessary to obtain activity similar in degree to that obtained by the lipid A moiety, the activity of which was also much weaker than that of K03 LPS (23). Recently, it has been reported that poly saccharides isolated from diverse sources have considerable antitumor activity against certain allogeneic tumors, particularly S-180 implanted in mice (13-17). Moreover, a protein-bound glucan has also been reported to show strong antitumor activity against S 180 and is used clinically as an antitumor drug (13). The glucans which were reported to have antitumor activity consist mainly of 1, 3 linkages, and their antitumor action may be host-mediated, although their exact mechanisms are still unknown.
In the present study, we investigated whether OPS has antitumor activity against mice bearing syngeneic ascites tumor (MM2 mammary carcinoma), syngeneic solid type tumor (Meth-A fibrosarcoma), or allogeneic solid type tumor (S-180). OPS could elicit a marked increase in the life span of mice bearing MM2 ascites tumor by i.p. adminis tration. However, OPS showed no growth inhibitory activity against Meth-A tumor by i.p., i.v. or i.t. administration.
In the case of allogeneic tumor, large amounts of OPS showed growth-inhibitory activity by i.p. administration, but did not show any sig nificant activity by p.o. administration.
On the other hand, it has been reported that mannans obtained from fungi exhibited significant antitumor activity against S-180 solid type tumor at low doses by i.p. adminis tration (25). The results of this study suggest that the differences of antitumor activity in the mannan and OPS seem to be based on the differences in their molecular structures. Moreover, in their screening test, treatment was started at 1 day after s.c. transplantation of the tumor cells.
On the other hand, it was shown that K03 LPS exhibits a strong antitumor activity against both allogeneic and syngeneic tumors in mice. In particular, i. 443-454 (1974) 
